Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia

被引：0

作者：

Davidson, Michael ^{[1
,2
]}

Noel, Nadine ^{[3
]}

Schmitt, Florent ^{[3
]}

Luthringer, Remy ^{[1
]}

机构：

[1] Minerva Neurosci, 1500 Dist Ave, Burlington, MA 01803 USA

[2] Nicosia Univ, Med Sch, Clin & Basic Sci Dept, Nicholas St 93, CY-2408 Egkomi Lefkosias, Cyprus

[3] PPRS, PPRS SAS, 4e Av Gen Gaulle, F-68000 Colmar, France

来源：

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2025年 / 28卷 / 06期

关键词：

schizophrenia; negative symptoms; treatment; roluperidone; PHENCYCLIDINE; DRUG; INVOLVEMENT; DOMAIN;

D O I：

10.1093/ijnp/pyaf032

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration.Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.

引用

页数：4

共 28 条

[1] Structures of the σ2, receptor enable docking for bioactive ligand discovery [J].

Alon, Assaf ;

Lyu, Jiankun ;

Braz, Joao M. ;

Tummino, Tia A. ;

Craik, Veronica ;

O'Meara, Matthew J. ;

Webb, Chase M. ;

Radchenko, Dmytro S. ;

Moroz, Yurii S. ;

Huang, Xi-Ping ;

Liu, Yongfeng ;

Roth, Bryan L. ;

Irwin, John J. ;

Basbaum, Allan, I ;

Shoichet, Brian K. ;

Kruse, Andrew C. .

NATURE, 2021, 600 (7890) :759-+

[2] ACUTE AND CHRONIC PHENCYCLIDINE EFFECTS ON LOCOMOTOR-ACTIVITY, STEREOTYPY AND ATAXIA IN RATS [J].

CASTELLANI, S ;

ADAMS, PM .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1981, 73 (2-3) :143-154

[3] Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence [J].

Davidson, Michael ;

Carpenter Jr, William T. .

SCHIZOPHRENIA BULLETIN, 2024, 50 (01) :14-21

[4] Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia [J].

Davidson, Michael ;

Saoud, Jay ;

Staner, Corinne ;

Noel, Nadine ;

Werner, Sandra ;

Luthringer, Elisabeth ;

Walling, David ;

Weiser, Mark ;

Harvey, Philip D. ;

Strauss, Gregory P. ;

Luthringer, Remy .

SCHIZOPHRENIA BULLETIN, 2022, 48 (03) :609-619

[5] Do DSM classifications help or hinder drug development? [J].

Davidson, Michael ;

Gabos-Grecu, Cristian .

DIALOGUES IN CLINICAL NEUROSCIENCE, 2020, 22 (01) :73-79

[6] Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia [J].

Davidson, Michael ;

Saoud, Jay ;

Staner, Corinne ;

Noel, Nadine ;

Luthringer, Elisabeth ;

Werner, Sandra ;

Reilly, Joseph ;

Schaffhauser, Jean-Yves ;

Rabinowitz, Jonathan ;

Weiser, Mark ;

Luthringer, Remy .

AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (12) :1195-1202

[7]

DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474

[8] Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery? [J].

Harrow, Martin ;

Jobe, Thomas H. .

SCHIZOPHRENIA BULLETIN, 2013, 39 (05) :962-965

[9] Neuroscience of apathy and anhedonia: a transdiagnostic approach [J].

Husain, Masud ;

Roiser, Jonathan P. .

NATURE REVIEWS NEUROSCIENCE, 2018, 19 (08) :470-484

[10] Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders [J].

Insel, Thomas ;

Cuthbert, Bruce ;

Garvey, Marjorie ;

Heinssen, Robert ;

Pine, Daniel S. ;

Quinn, Kevin ;

Sanislow, Charles ;

Wang, Philip .

AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (07) :748-751

← 1 2 3 →